We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Gemcitabine-Induced Subacute Cutaneous Lupus Erythematosus: A Case Report.
- Authors
Ben Zvi, Masha; Vaknine, Hananya; Menczer, Joseph; Peled, Ofri; Ben Shem, Erez; Schreiber, Letizia; Levy, Tally
- Abstract
Subacute cutaneous lupus erythematosus (SCLE) is a rare eruption related to several pharmacological and chemotherapy agents. We present a 63-year-old female with recurrent epithelial ovarian cancer who developed SCLE after administration of gemcitabine. Following discontinuation of gemcitabine and after oral steroid treatment, all skin lesions disappeared. In view of the extensive use of gemcitabine in recurrent ovarian cancer, it is important to be aware of the possibility of SCLE occurrence in these patients. Subacute cutaneous lupus erythematosus (SCLE) was first defined in 1979 by Sontheimer et al. [1] as a subset of cutaneous lupus erythematosus. SCLE presents clinically with nonscarring, erythematous annular or papulosquamous cutaneous eruptions in sun-exposed areas. About 75% of patients with SCLE present Ro/SSA autoantibodies [2]. In 1985, Reed et al. [3] were the first to describe a series of 5 patients in whom hydrochlorothiazide was implicated as the causative factor. Since then, many other drugs, including several chemotherapeutic agents, have been related to SCLE [2, 4]. To our knowledge, there is only one previous case report describing gemcitabine treatment as causative of SCLE [4]. Herein, we present another case report of SCLE related to monotherapeutic gemcitabine.
- Subjects
OVARIAN cancer; DRUG-induced abnormalities; STEROIDS; CUTANEOUS therapeutics
- Publication
Chemotherapy (0009-3157), 2016, Vol 61, Issue 5, p236
- ISSN
0009-3157
- Publication type
Article
- DOI
10.1159/000443762